Nancy F Olivieri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4336498/publications.pdf

Version: 2024-02-01

40 papers	3,631 citations	430754 18 h-index	360920 35 g-index
40 all docs	40 docs citations	40 times ranked	2294 citing authors

#	Article	IF	Citations
1	Iron-Chelating Therapy and the Treatment of Thalassemia. Blood, 1997, 89, 739-761.	0.6	971
2	Survival in Medically Treated Patients with Homozygous Î²-Thalassemia. New England Journal of Medicine, 1994, 331, 574-578.	13.9	829
3	Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major. New England Journal of Medicine, 1998, 339, 417-423.	13.9	389
4	Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major. New England Journal of Medicine, 1995, 332, 918-922.	13.9	306
5	Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia Major. New England Journal of Medicine, 1985, 312, 1600-1603.	13.9	269
6	Iron overload cardiomyopathies: New insights into an old disease. Cardiovascular Drugs and Therapy, 1994, 8, 101-110.	1.3	128
7	Studies in haemoglobin E betaâ€thalassaemia. British Journal of Haematology, 2008, 141, 388-397.	1.2	103
8	Critical Comparison of Novel and Existing Methods of Compliance Assessment During a Clinical Trial of an Oral Iron Chelator. Journal of Clinical Pharmacology, 1994, 34, 944-949.	1.0	79
9	Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood, 2012, 119, 2746-2753.	0.6	78
10	Patientsâ€™ health or company profits? The commercialisation of academic research. Science and Engineering Ethics, 2003, 9, 29-41.	1.7	60
11	Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clinical Pharmacology and Therapeutics, 1991, 50, 294-298.	2.3	51
12	Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 38.	1.6	47
13	Hb E/beta-thalassaemia: a common & clinically diverse disorder. Indian Journal of Medical Research, 2011, 134, 522-31.	0.4	37
14	Pain Perception and Effectiveness of the Eutectic Mixture of Local Anesthetics in Children Undergoing Venipuncture. Pediatric Research, 1992, 32, 520-523.	1.1	35
15	Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine. American Journal of Hematology, 1992, 41, 61-63.	2.0	34
16	HbE/Î²-Thalassemia: Basis of Marked Clinical Diversity. Hematology/Oncology Clinics of North America, 2010, 24, 1055-1070.	0.9	34
17	Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. PLoS ONE, 2019, 14, e0211942.	1.1	29
18	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. British Journal of Haematology, 2015, 169, 887-898.	1.2	22

#	Article	IF	Citations
19	Deferiprone and hepatic fibrosis. Blood, 2003, 101, 5089-5091.	0.6	18
20	A Phase II Study with ICL670 (ExjadeÂ®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.. Blood, 2004, 104, 3193-3193.	0.6	17
21	Treatment strategies for hemoglobin E beta-thalassemia. Blood Reviews, 2012, 26, S28-S30.	2.8	15
22	Iron status and anaemia in Sri Lankan secondary school children: A cross-sectional survey. PLoS ONE, 2017, 12, e0188110.	1.1	15
23	Long-Term Trials of Deferiprone in Cooley's Anemiaa. Annals of the New York Academy of Sciences, 1998, 850, 217-222.	1.8	13
24	Emerging insights in the management of hemoglobin E beta thalassemia. Annals of the New York Academy of Sciences, 2010, 1202, 155-157.	1.8	12
25	Headache: an important symptom possibly linked to white matter lesions in thalassaemia. British Journal of Haematology, 2019, 185, 541-548.	1.2	7
26	Oxidative status in the Î²-thalassemia syndromes in Sri Lanka; a cross-sectional survey. Free Radical Biology and Medicine, 2021, 166, 337-347.	1.3	6
27	Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study. The Lancet Global Health, 2022, 10, e134-e141.	2.9	6
28	Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. Blood, 2009, 114, 4056-4056.	0.6	5
29	Improving Laboratory and Clinical Hematology Services in Resource Limited Settings. Hematology/Oncology Clinics of North America, 2016, 30, 497-512.	0.9	4
30	A â€œOne-Stopâ€•Screening Protocol for Haemoglobinopathy Traits and Iron Deficiency in Sri Lanka. Frontiers in Molecular Biosciences, 2019, 6, 66.	1.6	3
31	Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997â€“2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine, 2021, 31, 100693.	3.2	3
32	Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study.. Blood, 2009, 114, 2016-2016.	0.6	3
33	Progression of Avascular Necrosis of the Hip in Sickle Cell Disease: 2 Year Follow-Up of Randomized Trial of Aggressive Physical Therapy and Hip Coring Decompression.. Blood, 2004, 104, 1685-1685.	0.6	1
34	Renal Dysfunction in Thalassemia.. Blood, 2009, 114, 2008-2008.	0.6	1
35	Rates of Non-Transfusional Iron Accumulation (NTIA) In Hemoglobin E Thalassemia. Blood, 2010, 116, 5147-5147.	0.6	1
36	Low Bone Mass in Thalassemia: The Thalassemia Clinical Research Network (TCRN) Experience.. Blood, 2004, 104, 3613-3613.	0.6	0

#	Article	IF	Citations
37	Hemoglobin H-Constant Spring in North America: A Common Alpha Thalassemia with Frequent Complications.. Blood, 2008, 112, 1880-1880.	0.6	0
38	Body Composition and Its Relationship to Growth and Bone Mass in Patients with Thalassemia. Blood, 2008, 112, 3890-3890.	0.6	0
39	Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.. Blood, 2008, 112, 1868-1868.	0.6	0
40	Phenomenon of Pain In Thalassemia: A Prospective Analysis by the Thalassemia Clinical Research Network (TCRN). Blood, 2010, 116, 256-256.	0.6	0